

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

APR 18 2008

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/542,279
Filing Date	July 15, 2005
First Named Inventor	Helga Schleenhain
Art Unit	4173
Examiner Name	Samira JM Jean-Louis
Attorney Docket Number	82182

Sheet

of

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Scholtz et al., "Treatment of Vertigo Due to Acute Unilateral Vestibular Loss with a Fixed Combination of Cinnarizine and Dimenhydrinate: A Double-Blind, Randomized, Parallel-Group Clinical Study," Clinical Therapeutics, 26(6):866-77 (2004)	
	2	Cirek et al., "Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo," Clin. Drug. Invest., 25(6):377-89 (2005)	
	3	"Dimenhydrinat kombiniert mit Cinnarizin hilft," Therapiewoche, 46(3):175 (1996)	
	4	Novotny et al., "The Efficacy of Arlevert Therapy for Vertigo and Tinnitus," International Tinnitus Journal, 5(1):60-2 (1999)	
	5	"Schwindeltherapie mit Cinnarizin und Dimenhydrinat: Kombinationsbehandlung ist effektiver," T&E Neurologie Psychiatrie, 11(12):927-8 (1997)	
	6	Novotny et al., "Fixed Combination of Cinnarizine and Dimenhydrinate Versus Betahistine Dimesylate in the Treatment of Meniere's Disease: A Randomized, Double-Blind, Parallel Group Clinical Study," International Tinnitus Journal, 8(2):115-23 (2002)	

Examiner  
Signature

/Samira Jean-louis/

Date  
Considered

07/14/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./